BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 16980008)

  • 1. Treatment of oropharyngeal cancer in renal transplant recipients without cessation of immunosuppressive therapy.
    Singh SK; Gupta AK; Jha V; Kohli HS; Gupta KL; Minz M; Sakhuja V
    Transplant Proc; 2006 Sep; 38(7):2088-9. PubMed ID: 16980008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urological malignancy as a complication of renal transplantation: a report of twelve clinical cases.
    Zhou M; Zhu Y; Wang L; Wang Y; Fu S; Min Z
    Clin Transpl; 2006; ():395-8. PubMed ID: 18365395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of tongue cancer in the patient who is systemically immunosuppressed: a preliminary report.
    Meng S; Jiamei L
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2000 Dec; 90(6):689-93. PubMed ID: 11113812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful tapering of immunosuppression to low-dose monotherapy steroids after living-related human leukocyte antigen-identical renal transplantation.
    van de Wetering J; Gerrits JH; van Besouw NM; Ijzermans JN; Weimar W
    Transplantation; 2009 Mar; 87(5):740-4. PubMed ID: 19295320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppressive therapy and Kaposi's sarcoma after kidney transplantation.
    Moray G; Başaran O; Yağmurdur MC; Emiroğlu R; Bilgin N; Haberal M
    Transplant Proc; 2004; 36(1):168-70. PubMed ID: 15013336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urological malignancy after renal transplantation.
    Besarani D; Cranston D
    BJU Int; 2007 Sep; 100(3):502-5. PubMed ID: 17669141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of Kaposi's sarcoma and graft following discontinuation of immunosuppressive drugs in renal transplant recipients.
    Firoozan A; Hosseini Moghaddam SM; Einollahi B; Pour-Reza-Gholi F; Nafar M; Basiri A; Ebrahimi-Rad R
    Transplant Proc; 2005 Sep; 37(7):3061-4. PubMed ID: 16213305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.
    Boratyńska M; Watorek E; Smolska D; Patrzałek D; Klinger M
    Transplant Proc; 2007 Nov; 39(9):2736-9. PubMed ID: 18021973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma in renal transplant recipients.
    Chuang CH; Chien YS; Cheng YT; Chen YT; Hu TH; Hsieh H
    Transplant Proc; 2008 Sep; 40(7):2392-4. PubMed ID: 18790244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation.
    Manuelli M; De Luca L; Iaria G; Tatangelo P; Sforza D; Perrone L; Bellini MI; Angelico R; Anselmo A; Tisone G
    Transplant Proc; 2010 May; 42(4):1314-6. PubMed ID: 20534289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience.
    Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Bayoumy A; Sobh M; Ghoneim M
    Iran J Kidney Dis; 2008 Jan; 2(1):34-9. PubMed ID: 19367007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-skin solid tumors as a cause of morbidity and mortality after liver transplantation.
    Fraile P; García-Cosmes P; Martín P; García-Bernalt V; Tabernero JM
    Transplant Proc; 2009; 41(6):2433-4. PubMed ID: 19715943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors and prognosis for proteinuria in renal transplant recipients.
    Sancho A; Gavela E; Avila A; Morales A; Fernández-Nájera JE; Crespo JF; Pallardo LM
    Transplant Proc; 2007 Sep; 39(7):2145-7. PubMed ID: 17889119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
    Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporine withdrawal improves long-term graft survival in renal transplantation.
    Gallagher M; Jardine M; Perkovic V; Cass A; McDonald S; Petrie J; Eris J
    Transplantation; 2009 Jun; 87(12):1877-83. PubMed ID: 19543068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized study comparing cyclosporine with azathioprine one year after renal transplantation-15-year outcome data.
    Joss N; Rodger RS; McMillan MA; Junor BJ
    Transplantation; 2007 Mar; 83(5):582-7. PubMed ID: 17353778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Incidence of de novo neoplasms after liver transplantation].
    Berenguer M; Prieto M; Bustamante M; Carrasco D; López-Andújar R; Mir J; Berenguer J
    Med Clin (Barc); 1998 Oct; 111(13):481-4. PubMed ID: 9859063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.